Reopoliglyukin Sukhoi

Reopoliglucin Dry: Plasma substitute and detoxification solution based on dextran

Reopoliglucin Sukhoi is a pharmaceutical drug developed in Russia. It belongs to the group of plasma replacement and detoxification solutions based on dextran. The drug is produced by Kraspharma in Russia and has the international name "Dextran" with a molecular weight of about 35,000.

Reopoliglucin Dry is a substance in the form of a 10% colloidal solution of partially hydrolyzed dextran with a molecular weight of 30,000 to 40,000, supplemented with an isotonic solution of sodium chloride.

The drug is used in various pathological conditions accompanied by impaired blood circulation in peripheral vessels, as well as in shock. It is also used for detoxification of burns and peritonitis.

Despite its effectiveness, Reopoliglyukin Sukhoi has some contraindications. It is not recommended for thrombocytopenia, kidney disease and heart failure.

Side effects from using the drug may include allergic reactions.

There is no information on the interaction of Reopoliglucin Sukhoi with other drugs. There is also no data on overdose and special instructions for the use of the drug.

The official source of information about Reopoliglyukin Sukhoi and its properties is the reference book "Medicines", edited by M. A. Klyuev, published in 2001.

conclusions

Reopoliglucin Sukhoi is an effective plasma substitute and detoxification solution based on dextran. The drug is used to treat pathological conditions accompanied by impaired blood circulation and, if necessary, detoxification. However, before using Reopoliglucin Sukhoi, it is necessary to take into account contraindications and possible adverse reactions, and also consult a medical specialist.